EUCTR2016-002426-37-DE进行中（未招募）1 期
Randomized, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of 2 Prospan® posologies (2x 7.5 mL/day and 3x 5 mL/day) in the treatment of acute bronchitis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Acute bronchitis with symptoms lasting 48 to 72 hours prior to treatment
- •2) Men or women of any ethnic origin
- •3) Age 18 to 75 years
- •4) Subjects who are able to understand and are willing to comply to trial instructions
- •5) Having given written informed consent
- •6) Satisfactory health except for the bronchitis as determined by the investigator based on medical history and physical examination
- •7) CS score of at least 50 mm on a 100 mm VAS at V1
- •8) BSS of at least 10 points at V1
- •9) VCD score of at least 2 points at V1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 193
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 17
排除标准
- •1) Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other chronic or inherited lung disease
- •2) History of hypersensitivity to any excipient of the applied drugs
- •3) History of drug hypersensitivity, asthma, urticaria, or other severe allergic diathesis as well as current hay fever
- •4) History of chronic gastritis or peptic ulcers
- •5) Any gastrointestinal complaints within 7 days before V1
- •6) Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly
- •7) Treatment with corticoids, beta-2 agonists (e.g. salbutamol, fenoterol), expectorants, theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other non-steroidal anti-inflammatory drugs, leukotriene inhibitors, angiotensin-converting enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines, immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs against common cold within 7 days before V1
- •8) Drug or alcohol abuse in the opinion of the investigator
- •9) Pregnant or nursing (lactating) women
- •10) Body temperature >38.3°C
- •11) Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as:
- •Surgical sterilization
- •Hormonal contraception
- •Intra-Uterine Device (IUD)
- •Double barrier method
- •Total abstinence throughout the trial at the discretion of the investigator
- •Periodic abstinence is NOT an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the trial.
- •A woman who is post-menopausal must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of child-bearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •12) Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject’s ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease.
- •13) Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.
研究者
相似试验
进行中（未招募）
1 期
Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis. Estudio aleatorizado, controlado con placebo, en doble ciego y multicéntrico, para evaluar la seguridad y la eficacia de ciprofloxacino inhalado frente a placebo en pacientes con bronquiectasias no debidas a fibrosis quística.Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of greater than or equal to 35 % and less than or equal to 80 percent of predicted) Bronquiectasias idiopática y post-neumónica no debidas a fibrosis quística en pacientes en situación pulmonar estable (definida como mayor o igual al 35% y menor o igual al 80%)MedDRA version: 9.1 Level: LLT Classification code 10006445 Term: BronchiectasisMedDRA version: 9.1 Level: PT Classification code 10006445 Term: BronchiectasisEUCTR2009-009869-34-ESBayer HealthCare AG
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)MedDRA version: 9.1Level: LLTClassification code 10006445Term: BronchiectasisMedDRA version: 9.1Level: PTClassification code 10006445Term: BronchiectasisEUCTR2009-009869-34-DEBayer HealthCare AG122
进行中（未招募）
1 期
Efficacy, safety and tolerability of Arikace™ compared to placebo in Cystic Fibrosis patients with chronic infection due to Pseudomonas AeruginosaPseudomonas aeruginosa pulmonary infection / colonisation in patientswith cystic fibrosisMedDRA version: 14.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000442-38-PLInsmed Incorporated300
进行中（未招募）
1 期
Clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adult patients with recently diagnosed asymptomatic to moderately severe COVID-19.SARS-CoV2 treatment.MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-005532-29-ITToscana Life Sciences Sviluppo806
进行中（未招募）
不适用
Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939EUCTR2009-009869-34-GBBayer HealthCare AG122